Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon

ASTRO and AAPM announce RO-ILS: Radiation Oncology Incident Learning System (RO-ILS)

Together, the American Society for Radiation Oncology (ASTRO) and the American Association of Physicists in Medicine (AAPM) will share details about RO-ILS: Radiation Oncology Incident Learning System, a new, national patient safety initiative to facilitate safer and higher quality radiation oncology care.

Personalized care from disease detection through treatment assessment enabled with GE Healthcare’s Discovery IQ

During the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation, helping physicians deliver the best possible patient outcomes.

Thumbnail

Lymphoseek: Newly approved for oral cavity cancer, more expansion expected

Lymphoseek, otherwise known as technetium Tc-99m tilmanocept, is now available for use in sentinel lymph-node mapping of patients with cases of head and neck cancer. Producer Navidea Biopharmaceuticals, based in Dublin, Ohio, held a teleconference for stakeholders yesterday to discuss the expanded approval.

NorthStar Medical teams with Triad for domestic supply of moly

NorthStar Medical Radioisotopes, based in Madison, Wis., announced a non-exclusive letter of intent yesterday with major radiopharmacy chain Triad Isotopes in an effort to provide a U.S. source of molybdenum-99 (Mo-99), which decays to produce technetium-99m (Tc-99m), used in the lion's share of nuclear medicine procedures.

FDA approves Lymphoseek to help determine the extent of head and neck cancer in the body

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body’s head and neck region.

GE Healthcare Launches Interactive Patient Profiler for AdreView (Iobenguane I 123 Injection)

The Interactive Patient Profiler for AdreView is a simulation tool designed to help educate physicians on the use of AdreView (Iobenguane I 123 Injection) to assess mortality risk in patients with heart failure. The tool demonstrates the types of patients where the use of AdreView can provide further information to assist physicians in identifying patients who may have a lower one- and two-year mortality risk, among groups of patients with similar profiles based on other clinical information.

SNMMI 2014: Interview with Barry A. Siegel, MD, winner of Cassen Prize

As the 2014 Annual Meeting for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) came to a close this year, Molecular Imaging sat down with Barry A. Siegel, MD, professor of radiology and medicine and chief of the nuclear medicine division at Washington University School of Medicine here in St. Louis. Siegel was honored this year with the most prestigious award presented during the meeting: the Benedict Cassen Prize.

MAA price spike: Jubilant DraxImage address dodges antitrust concern

General discontent followed a one-time, exponential price hike from Jubilant DraxImage starting April 1 for the company’s exclusive MAA kit for the preparation of technetium-99m albumin, a lung perfusion agent. An industry forum on challenges in the radiopharmaceutical realm presented during the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014 Annual Meeting in St. Louis featured a panel of speakers, including vice president of sales, marketing and business development for JDI, Kevin Brooks, who made a case for the company.

Displaying 737 - 744 of 1400
Design by Adaptive Theme